Fig. 1From: PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer modelsEffects of single and dual MET/PI3K inhibition on phosphorylation of PI3K downstream targets AKT and S6 after 16 h of treatment. a, single treatment with increasing concentrations of MET inhibitor tepotinib (0-100 nM); b, PI3K inhibitor pictilisib (0-100 nM). c, single vs. dual MET/PI3K inhibitionBack to article page